BioNTech (BNTX) cautioned that proposed healthcare reforms in Germany, due for a vote this summer, could put future investments in the country at risk, Bloomberg reported Wednesday, citing Chief Commercial Officer Annemarie Hanekamp.

Hanekamp said future investments in Germany will depend on whether policymakers can establish a stable and predictable framework for pharmaceutical companies, according to the report.

The proposals, which aim to lower drug prices to curb healthcare costs, could also have implications for the US, the report added.

BioNTech did not immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 88.31, Change: -0.83, Percent Change: -0.93